Related Experiment Video

Updated: Jun 28, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

958

Meningioma achieves malignancy and erastin-induced ferroptosis resistance through FOXM1-AURKA-NRF2 axis

Yangfan Ye1, Lei Xu1, Liuchao Zhang1

  • 1Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.

Redox Biology
|April 20, 2024
PubMed

Insights

Aurora kinase A (AURKA) drives high-grade meningioma by suppressing ferroptosis. Inhibiting AURKA alongside ferroptosis inducers like erastin improves tumor prognosis in mice, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Aurora kinase A (AURKA) is an oncogene linked to various cancers, but its role in meningioma is unknown.
  • Recent research suggests a connection between AURKA and ferroptosis, a regulated cell death pathway, though mechanisms are unclear.

Purpose of the Study:

  • To investigate the role of AURKA in meningioma progression and its association with ferroptosis.
  • To elucidate the molecular mechanisms by which AURKA influences ferroptosis in meningioma cells.

Main Methods:

  • Assessed AURKA expression in high-grade meningioma tissues.
  • Investigated AURKA's interaction with KEAP1 and its effect on NRF2 activation.
  • Examined the role of FOXM1 in AURKA transcription.
  • Evaluated the therapeutic effect of combined AURKA inhibition and erastin in a meningioma mouse model.

Main Results:

  • AURKA is upregulated in high-grade meningioma, enhancing malignant characteristics.
  • AURKA suppresses erastin-induced ferroptosis by phosphorylating KEAP1, leading to NRF2 activation.
  • FOXM1 promotes AURKA transcription.
  • Combined AURKA suppression and erastin treatment significantly improved prognosis in a meningioma murine model.

Conclusions:

  • AURKA acts as a suppressor of ferroptosis in meningioma through the KEAP1-NRF2 pathway.
  • FOXM1-mediated transcription of AURKA contributes to meningioma pathogenesis.
  • Combination therapy targeting AURKA and inducing ferroptosis shows therapeutic potential for meningioma.
Keywords:
AURKAFerroptosisMeningiomaNRF2Protein kinase

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K